港股异动 | CRO概念股涨幅居前花旗指美对华药企授权政策前景偏正面继续看好创新药及生物科技

智通财经09-25 13:50

【港股异动 | CRO概念股涨幅居前花旗指美对华药企授权政策前景偏正面继续看好创新药及生物科技】智通财经APP获悉，CRO概念股涨幅居前，截至发稿，金斯瑞生物科技(01548.HK)涨9.16%，报43.38港元；凯莱英(06821.HK)涨3.81%，报155.4港元；药明康德(02359.HK)涨2.44%，报210港元；药明生物(02269.HK)涨2.31%，报53.1港元；泰格医药(03347.HK)涨1.15%，报45.62港元。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2670944836?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-25 13:50","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2670944836","market":"hk","top_or_hot":-1,"title":"港股异动 | CRO概念股涨幅居前 花旗指美对华药企授权政策前景偏正面 继续看好创新药及生物科技","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【港股异动 | CRO概念股涨幅居前 花旗指美对华药企授权政策前景偏正面 继续看好创新药及生物科技】</b>智通财经APP获悉，CRO概念股涨幅居前，截至发稿，金斯瑞生物科技(01548.HK)涨9.16%，报43.38港元；凯莱英(06821.HK)涨3.81%，报155.4港元；药明康德(02359.HK)涨2.44%，报210港元；药明生物(02269.HK)涨2.31%，报53.1港元；泰格医药(03347.HK)涨1.15%，报45.62港元。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | CRO概念股涨幅居前 花旗指美对华药企授权政策前景偏正面 继续看好创新药及生物科技</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | CRO概念股涨幅居前 花旗指美对华药企授权政策前景偏正面 继续看好创新药及生物科技\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【港股异动 | CRO概念股涨幅居前 花旗指美对华药企授权政策前景偏正面 继续看好创新药及生物科技】</b>智通财经APP获悉，CRO概念股涨幅居前，截至发稿，金斯瑞生物科技(01548.HK)涨9.16%，报43.38港元；凯莱英(06821.HK)涨3.81%，报155.4港元；药明康德(02359.HK)涨2.44%，报210港元；药明生物(02269.HK)涨2.31%，报53.1港元；泰格医药(03347.HK)涨1.15%，报45.62港元。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2670944836","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2670944836","pubTimestamp":1790315418,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【港股异动 | CRO概念股涨幅居前 花旗指美对华药企授权政策前景偏正面 继续看好创新药及生物科技】智通财经APP获悉，CRO概念股涨幅居前，截至发稿，金斯瑞生物科技(01548.HK)涨9.16%，","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","06978":"永泰生物-B"},"translate_title":"Hong Kong Stocks in Focus | CRO Concept Stocks Lead Gains; Citigroup Says US Pharmaceutical Licensing Policy for Chinese Companies Has a Positive Outlook and Remains Optimistic About Innovative Drugs and Biotechnology","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06978":1.5},"content_text":"【港股异动 | CRO概念股涨幅居前 花旗指美对华药企授权政策前景偏正面 继续看好创新药及生物科技】智通财经APP获悉，CRO概念股涨幅居前，截至发稿，金斯瑞生物科技(01548.HK)涨9.16%，报43.38港元；凯莱英(06821.HK)涨3.81%，报155.4港元；药明康德(02359.HK)涨2.44%，报210港元；药明生物(02269.HK)涨2.31%，报53.1港元；泰格医药(03347.HK)涨1.15%，报45.62港元。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2670944836","isCrawlerRequest":true}

港股异动 | CRO概念股涨幅居前 花旗指美对华药企授权政策前景偏正面 继续看好创新药及生物科技

精彩评论

港股异动 | CRO概念股涨幅居前花旗指美对华药企授权政策前景偏正面继续看好创新药及生物科技